Drug intelligence / Profile preview

recanaclotide

Development stage: Phase 2
Lead developer: Ironwood Pharmaceuticals
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Oral

Overview

Recanaclotide is a synthetic peptide drug that acts as an agonist of the guanylate cyclase-C (GC-C) receptor. It was initially developed by Ironwood Pharmaceuticals for the treatment of gastrointestinal disorders such as functional dyspepsia and diabetic gastroparesis. The drug mimics the action of endogenous guanylin peptides by activating GC-C on intestinal epithelial cells, leading to increased cyclic GMP levels and promoting intestinal fluid secretion and motility. Recanaclotide reached Phase 2 clinical trials but its development has been discontinued[1][3][4].

Other names: RecanaclotidaCHEMBL3707244CHEMBL-3707244CHEMBL 3707244

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on recanaclotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recanaclotide.

Explore the full profile